# Effect of the Amplifi™ Vein Dilation System on Outflow Vein Dilation and AV Fistula Maturation (AMPLIFI-1)

Study · id `cardio:ct-nct07211035` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07211035](<https://clinicaltrials.gov/study/NCT07211035>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07211035

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 160 participants.

## Technical summary

Registry record NCT07211035. Randomized; single masking; primary purpose treatment. Start 2026-05-12 (actual); primary completion 2027-06-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 160 participants (planned count; ClinicalTrials.gov record NCT07211035, source copy `cardio:ctgov-nct07211035-2026-06-23`, retrieved 2026-10-26)
- Started: 2026-05-12 (actual) (ClinicalTrials.gov record NCT07211035, source copy `cardio:ctgov-nct07211035-2026-06-23`, retrieved 2026-10-26)
- Primary completion: 2027-06-01 (anticipated) (ClinicalTrials.gov record NCT07211035, source copy `cardio:ctgov-nct07211035-2026-06-23`, retrieved 2026-10-26)
- Completion: 2027-12-01 (anticipated) (ClinicalTrials.gov record NCT07211035, source copy `cardio:ctgov-nct07211035-2026-06-23`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT07211035, source copy `cardio:ctgov-nct07211035-2026-06-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07211035-2026-06-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of the Amplifi™ Vein Dilation System on Outflow Vein Dilation and AV Fistula Maturation (AMPLIFI-1)
- Acronym: AMPLIFI-1
- Condition: End Stage Kidney Disease (ESRD)
- Intervention (Device): The Amplifi System is a temporary extracorporeal blood pump designed to deliver controlled flow through a peripheral vein for 24-72 hours prior to AVF creation.
- Intervention (Procedure): Standard of Care (AVF creation)
- Lead sponsor: Amplifi Vascular, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)

## Provenance

Content hash: a35820fcecca3602eaf09bfb8a897371b148089efcb9f55a64743ddedfa507e9
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
